To evaluate the levels of coagulation and fibrinolytic markers during the first trimester of pregnancy in women with polycystic ovary syndrome (PCOS) and determine the effects of PCOS and obesity on the levels of these hemostatic markers.
Methods:
A cross-sectional study was conducted in Beijing, China, on women with PCOS (n = 50), healthy women (n = 50), pregnant women with PCOS (n = 50), and healthy pregnant women (n = 50) at 12 weeks of pregnancy. Coagulation and fibrinolytic parameters were measured.
Results:
The interaction between PCOS and pregnancy appears to exert effects on the activities of coagulation factors VIII and X. The interaction between PCOS and obesity also seems to affect the level of von Willebrand factor.
Conclusions:
Pregnant women with PCOS, especially women who are obese, are observed to be in a more prohemostatic state during the first trimester.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–47.
2.
PanidisDMacutDTziomalosKPrevalence of metabolic syndrome in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2013;78(4):586–592.
3.
CarmassiFDe NegriFFioritiRInsulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome. Thromb Res. 2005;116(3):207–214.
4.
LindholmABixoMEliassonMTissue plasminogen activator and plasminogen activator inhibitor-1 in obese and lean patients with polycystic ovary syndrome. Gynecol Endocrinol. 2010;26(10):743–748.
5.
KoiouETziomalosKDinasKPlasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome. Endocr J. 2012;59(1):21–29.
6.
Mannerås-HolmLBaghaeiFHolmGCoagulation and Fibrinolytic Disturbances in Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2011;96(4):1068–1076.
7.
BrennerB. Haemostatic changes in pregnancy. Thromb Res. 2004;114(5-6):409–414.
8.
CoolmanMde GrootCJSteegersEAConcentrations of plasminogen activators and their inhibitors in blood preconceptionally, during and after pregnancy. Eur J Obstet Gynecol Reprod Biol. 2006;128(1-2):22–28.
9.
KjerulffLESanchez-RamosLDuffyD.Pregnancy outcomes in women with polycystic ovary syndrome : a metaanalysis. Am J Obstet Gynecol. 2011;204(6):558.e1–e6.
10.
GlueckCJWangPBornovaliSGoldenbergNSieveL. Polycystic Ovary Syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with recurrent pregnancy loss. Metabolism. 2003;52(12):1627–1632.
11.
YogevYMelamedNBardinRTenenbaum-GavishKBen-ShitritGBen-HaroushA.Pregnancy outcome at extremely advanced maternal age. Am J Obstet Gynecol. 2010;203(6):558.e1–e7.
12.
Le RayCScherierSAnselemOAssociation between oocyte donation and maternal and perinatal outcomes in women aged 43 years or older. Hum Reprod. 2012;27(3):896–901.
13.
Dossenbach-GlaningerAvan TrotsenburgMKruglugerWElevated coagulation factor VIII and the risk for recurrent early pregnancy loss. Thromb Haemost. 2004;91(4):694–699.
14.
SangleGVZhaoRShenGX. Transmembrane signaling pathway mediates oxidized low-density lipoprotein-induced expression of plasminogen activator inhibitor-1 in vascular endothelial cells. Am J Physiol Endocrinol Metab. 2008;295(5):E1243–E1254.
15.
GerritsAJKoekmanCAvan HaeftenTWAkkermanJW. Platelet tissue factor synthesis in type 2 diabetic patients is resistant to inhibition by insulin. Diabetes. 2010;59(6):1487–1495.
16.
GodslandIFCrookDProudlerAJStevensonJC. Hemostatic risk factors and insulin sensitivity, regional body fat distribution, and the metabolic syndrome. J Clin Endocrinol Metab. 2005;90(1):190–197.
17.
SambolaAOsendeJHathcockJRole of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation. 2003;107(7):973–977.
18.
BasaranA. Pregnancy-induced hyperlipoproteinemia: review of the literature. Reprod Sci. 2009;16(5):431–437.
19.
RangarajanS. Von Willebrand factor – two sides and the edge of a coin. Haemophilia. 2011;17(1):61–64.
20.
KoiouETziomalosKKatsikisIPlasma von Willebrand factor antigen levels are elevated in the classic phenotypes of polycystic ovary syndrome. Hormones (Athens). 2012;11(1):77–85.
21.
ChenHZhouLMengLCoagulation and prothrombotic state parameters: a clinical analysis during early pregnancy. Ir J Med Sci. 2011;180(4):813–817.
22.
KebapcilarLTanerCEKebapcilarAGSariI. High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome. Arch Gynecol Obstet. 2009;280(2):187–193.
23.
KebapcilarLTanerCEKebapcilarAGAlacaciogluASariI. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Arch Gynecol Obstet. 2010;281(1):35–42.
24.
PuccettiLBruniFPasquiALDyslipidemias and fibrinolysis. Ital Heart J. 2002;3(10):579–586.
25.
SteinbergHOBaronAD. Vascular function, insulin resistance and fatty acids. Diabetologia. 2002;45(5):623–634.
26.
MertensIVan der PlankenMCorthoutsBVan GaalLF. Is visceral adipose tissue a determinant of von Willebrand factor in overweight and obese premenopausal women?Metabolism. 2006;55(5):650–655.
27.
EkströmMLiskaJErikssonPSverremark-EkströmETornvallP. Stimulated in vivo synthesis of plasminogen activator inhibitor-1 in human adipose tissue. Thromb Haemost. 2012;108(3):485–492.
28.
JedelELabrieFOdénAImpact of electro-acupuncture and physical exercise on hyperandrogenism and oligo/amenorrhea in women with polycystic ovary syndrome: a randomized controlled trial. Am J Physiol Endocrinol Metab. 2011;300(1):E37–E45.
29.
KumarS.Occupational, Environmental and lifestyle factors associated with spontaneous abortion. Reprod Sci. 2011;18(10):915–930.
30.
BoomsmaCMEijkemansMJHughesEGVisserGHFauserBCMacklonNS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12(6):673–683.
